Robbins Geller Rudman & Dowd LLP Files Rocket Pharmaceuticals Class Action Lawsuit

Reading Time:

2

minutes

Posted: 8th July 2025

Jessica Bryant

Robbins Geller Rudman & Dowd LLP Files Rocket Pharmaceuticals Class Action Lawsuit.

Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit on behalf of investors who purchased or acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025 (the “Class Period”).

The case, Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), alleges violations of the Securities Exchange Act of 1934 and seeks to recover damages for investors who suffered losses due to misleading statements and material omissions by the company and a top executive.

According to the complaint, Rocket Pharmaceuticals misrepresented or failed to disclose serious safety concerns tied to its Phase 2 pivotal trial of RP-A501, a gene therapy for Danon disease.

Specifically, the lawsuit claims the company:

Introduced a new immunomodulatory agent into the trial protocol without notifying shareholders
Knew of Serious Adverse Events (SAEs), including a patient death, but concealed these risks
Amended the clinical protocol without disclosure, misleading investors on trial progress and safety

On May 27, 2025, Rocket revealed the FDA had placed a clinical hold on the trial after a patient died, causing the company’s stock to decline significantly.

Under the Private Securities Litigation Reform Act of 1995, investors have until August 11, 2025, to seek appointment as lead plaintiff. The lead plaintiff is typically the investor with the largest financial loss who meets certain legal standards to represent the class. That person or entity can direct the litigation and select counsel.

You do not need to serve as lead plaintiff to be eligible for any potential recovery from the class action.

If you purchased Rocket Pharmaceuticals securities during the Class Period and want to learn more, contact:

J.C. Sanchez or Jennifer N. Caringal
Phone: 800-449-4900
Email: info@rgrdlaw.com
Case Info: Rocket Pharmaceuticals Class Action

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a clinical-stage biotech company developing gene therapies for rare, life-threatening diseases using both AAV and lentiviral platforms. Based in New Jersey, Rocket’s lead program targets Danon disease and is in a Phase 2 pivotal trial.

Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities class action litigation, shareholder derivative actions, and consumer protection cases. Established in 1992, the firm has earned a reputation for its expertise in handling complex legal matters on behalf of institutional investors, individuals, and consumer groups. With a team of skilled attorneys, Robbins Geller is known for its dedication to securing justice and maximizing recoveries for clients, often representing those who have suffered significant financial losses. The firm has a history of success in landmark cases, and its attorneys are recognized as leaders in the field of securities litigation. Robbins Geller operates nationwide and has offices in major U.S. cities.